Related Experiment Video
Updated: Jun 22, 2025
Multimodality Diagnosis of Mesenteric Ischemia
Published on: July 21, 2023
[Impaired hemostasis in elderly and senile patients with mesenteric thrombosis in COVID-19.]
R V Kadnikov1, M V Vasilchenko2, A S Rukavishnikov1
1Saint-Petersburg Institute of Bioregulation and Gerontology, 3 Dynamo av., St. Petersburg 197119, Russian Federation,
Insights
COVID-19 significantly impacts the circulatory system, causing hemostasis disorders that increase thrombotic risks, especially in elderly patients. Understanding these changes is crucial for effective treatment and improved patient prognosis.
Area of Science:
- Internal Medicine
- Hematology
- Infectious Diseases
Background:
- COVID-19 presents complex challenges in patient management, particularly concerning circulatory system complications.
- Hemostasis disorders are recognized as a significant factor in the etiology and clinical progression of COVID-19.
- Thrombotic complications pose a serious threat, necessitating a deeper understanding of their underlying mechanisms.
Purpose of the Study:
- To review current literature on hemostasis disorders in elderly patients with COVID-19 and mesenteric thrombosis.
- To highlight the importance of identifying risk factors and interpreting hematological parameters for thrombotic complications.
- To discuss diagnostic criteria for various hemostasis disorders and guide therapeutic interventions.
Main Methods:
- Literature review focusing on hemostasis, COVID-19, mesenteric thrombosis, and elderly patients.
- Analysis of peripheral blood parameters and coagulograms in the context of COVID-19.
- Examination of diagnostic criteria for conditions like DIC syndrome, sepsis-associated coagulopathy, and hypercoagulation.
Main Results:
- Hemostasis dysfunction is a key contributor to severe COVID-19 outcomes, particularly in older adults.
- Early identification of thrombotic risk factors and appropriate interpretation of coagulation tests are vital.
- Specific hemostasis disorders, including DIC and hypercoagulation, are frequently observed in COVID-19 patients.
Conclusions:
- Effective management of COVID-19 requires a thorough understanding of hemostasis disorders and their impact on thrombosis.
- Differentiated therapeutic strategies, including anticoagulants and blood components, are essential for improving patient prognosis.
- Further research into hemostasis derangements in elderly COVID-19 patients with mesenteric thrombosis is warranted.
Abstract:
In the treatment of coronavirus infections, it is important not only to understand the course of the disease, but also to understand what is happening in the human body, especially in the circulatory system, that is, which disorders lead to deterioration and further complications. Hemostasis disorder in COVID-19 plays an important role in the etiology and clinical manifestations of the disease. The ability to identify factors and risk groups for the development of thrombotic complications, the ability to dynamically interpret peripheral blood parameters and coagulograms, knowledge of diagnostic criteria for possible hemostasis disorders (for example, DIC syndrome, sepsis-associated coagulopathy, antiphospholipids, hemophagocytosis and hypercoagulation syndrome) are necessary to determine the indications for the test. Differentiated prescribing of clinically justified therapy (including anticoagulants and blood components) is important, which determines the complexity of treatment and prognosis for patients with COVID-19. This article is a review of the literature on the topic of hemostasis disorders in elderly and senile patients with mesenteric thrombosis in COVID 19 over the past few years.
Related Concept Videos
01:24Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins